Wockhardt’s stock price has seen a dip of over 10% over the past quarter despite the company successfully launching its biotech based Hepatitis–B vaccine, integrating Merind’s operations and having six pharmaceutical brands in the ORG Top–300. (Dexolac, the company’s medical nutrition brand was the new entrant to the ORG Top 300 in the first half.)
Biovac–B, is reportedly giving a tough time to Engerix, SmithKline Pharma’s Hep–B vaccine having already sold a million doses (both paediatric and adult doses). Besides, the company has another biotech product erythoproetin (for the treatment of anaemia) slated for launch in the current year.
Even in anti–infectives (which contributes almost 29% of the company’s turnover) Wockhardt has launched Floxur (a quinolone antibiotic) which is targeting a Rs 510 m market growing at over 40% per annum.
Another promising business for the company is the infant nutrition business where its Dexolac brand registered a 33% growth in the first half.
Business wise performance
1H June 2000
1H June 1999
Bulk Drugs -Domestic
The key driver for Wockhardt stock from here on would be its success in the US generic market where it has filed seven patents already for NDDS already. The company already has a tie up with Sidmak Labs USA for distribution in place. It launched enalapril maleate (a cardiovascular formulation) tablets in the US generic market a month back, after the expiry of Merck’s patent.
The company is among the highest spenders on R & D and spends anywhere between Rs 400 m to Rs 450 m on R & D every year, it amortises over a period of three years. It is also estimated to clock exports of a Rs 1 bn in the current year.
We expect the company to report a net profit in the range of Rs 800 m (EPS: Rs 22.6) in the current year (the company accounting year ends in December) which implies an earnings multiple of less than 18 times.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407